PMID- 28498337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 7
IP  - 2
DP  - 2017 May 12
TI  - Imaging of Early Response to Predict Prognosis in the First-Line Management of 
      Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy.
LID - 10.3390/diagnostics7020026 [doi]
LID - 26
AB  - The purpose of this study was to evaluate prediction of prognosis after 
      first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma 
      (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography 
      with computed tomography ((18)F-FDG-PET/CT) three months after induction 
      treatment by Iodine-131-rituximab ((131)I-rituximab). Objective response was 
      determined using the Deauville 5-point scale in 68 prospective clinical trial 
      patients. Baseline (18)F-FDG-PET/CT studies were used to calculate 
      total-metabolic-tumor-volume (TMTV). Non-imaging studies included the Follicular 
      lymphoma international prognostic index (FLIPI) and absolute baseline monocyte 
      and lymphocyte counts. Patients were monitored for over ten years (median 
      follow-up 59 months), and no patient was lost to follow-up. Complete response 
      (CR) of 88% predicted excellent prognosis with median time-to-next-treatment 
      (TTNT) not yet reached. Those patients (12%) who failed to achieve CR (Deauville 
      </= 3) on (18)F-FDG-PET/CT at three months had significantly poorer outcomes (p < 
      0.0001) with a median TTNT of 41 months. Requirement for re-treatment was 
      predicted by FLIPI and absolute baseline monocyte count but not lymphocyte count. 
      The TTNT was accurately predicted by (18)F-FDG-PET/CT Deauville response at three 
      months following first-line therapy of FL with RIT. Early response demonstrated 
      by imaging does, therefore, foretell prognosis in the individual FL patients.
FAU - Kesavan, Murali
AU  - Kesavan M
AD  - Departments of Haematology and Nuclear Medicine, The University of Western 
      Australia, School of Medicine, Crawley 6009, Western Australia, Australia. 
      murali.kesavan@research.uwa.edu.au.
FAU - Boucek, Jan
AU  - Boucek J
AD  - Departments of Haematology and Nuclear Medicine, The University of Western 
      Australia, School of Medicine, Crawley 6009, Western Australia, Australia. 
      jan.boucek@health.wa.gov.au.
FAU - MacDonald, William
AU  - MacDonald W
AD  - Departments of Haematology and Nuclear Medicine, The University of Western 
      Australia, School of Medicine, Crawley 6009, Western Australia, Australia. 
      William.MacDonald@health.wa.gov.au.
FAU - McQuillan, Andrew
AU  - McQuillan A
AD  - Departments of Haematology and Nuclear Medicine, The University of Western 
      Australia, School of Medicine, Crawley 6009, Western Australia, Australia. 
      Andrew.McQuillan@health.wa.go.au.
FAU - Turner, J Harvey
AU  - Turner JH
AD  - Departments of Haematology and Nuclear Medicine, The University of Western 
      Australia, School of Medicine, Crawley 6009, Western Australia, Australia. 
      John.Turner@health.wa.gov.au.
LA  - eng
PT  - Journal Article
DEP - 20170512
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC5489946
OTO - NOTNLM
OT  - follicular lymphoma
OT  - non-Hodgkin lymphoma
OT  - outcome prediction
OT  - prognosis
OT  - radioimmunotherapy and PET imaging
COIS- The authors declare no conflict of interest.
EDAT- 2017/05/13 06:00
MHDA- 2017/05/13 06:01
PMCR- 2017/05/12
CRDT- 2017/05/13 06:00
PHST- 2017/02/27 00:00 [received]
PHST- 2017/05/04 00:00 [revised]
PHST- 2017/05/09 00:00 [accepted]
PHST- 2017/05/13 06:00 [entrez]
PHST- 2017/05/13 06:00 [pubmed]
PHST- 2017/05/13 06:01 [medline]
PHST- 2017/05/12 00:00 [pmc-release]
AID - diagnostics7020026 [pii]
AID - diagnostics-07-00026 [pii]
AID - 10.3390/diagnostics7020026 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2017 May 12;7(2):26. doi: 10.3390/diagnostics7020026.